Source: Annual Congress 2011 - Treating childhood asthma
Disease area: Airway diseases, Paediatric lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
J. Pitts, S. Sheikh, K. McCoy (Columbus, United States Of America). Safety and efficacy of omalizumab in children with allergic asthma. Eur Respir J 2011; 38: Suppl. 55, 4826

Member's Comments

No comment yet.

Related content which might interest you: Safety of omalizumab therapy in children with allergic asthma Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues Year: 2009 Efficacy and safety of ciclesonide in the treatment of patients with persistent allergic or non-allergic asthma Source: Annual Congress 2012 - Asthma treatment: efficacy and safety Year: 2012 Efficacy of montelukast in patients with concomitan persistent allergic rhinitis and asthma Source: Eur Respir J 2006; 28: Suppl. 50, 663s Year: 2006 Real-life long-term omalizumab therapy in children with severe allergic asthma Source: Eur Respir J 2015; 46: 856-859 Year: 2015 Efficacy of omalizumab in patients with concomitant allergic asthma and atopic dermatitis: a pilot study Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009 Assesment of long-term omalizumab treatment in severe allergic asthma Source: Annual Congress 2012 - Asthma: risk factors and effect of anti-IgE Year: 2012 Systemic steroid use in children with allergic (IgE-mediated) asthma receiving omalizumab Source: Annual Congress 2010 - Managing asthma and allergic disease in children Year: 2010 Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma Source: Eur Respir J 2002; 20: 73-78 Year: 2002 The effectiveness of omalizumab in steroid-dependent asthma patients Source: Annual Congress 2010 - Asthma: clinical aspects and treatment Year: 2010 The efficacy of desloratadine in the treatment of allergic rhinitis Source: Eur Respir J 2004; 24: Suppl. 48, 124s Year: 2004 The role of omalizumab or rhuMAb-E25 in the treatment of allergic rhinitis Source: Eur Respir J 2004; 24: 330 Year: 2004 Real-life effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 Is montelukast effective in allergic rhinitis in children? Source: Eur Respir J 2006; 28: Suppl. 50, 263s Year: 2006 Effectiveness of omalizumab in improving quality of life in patients with ‘steroid-resistant‘ asthma and severe allergic rhinitis Source: Annual Congress 2012 - Clinical aspects and treatment of asthma and allergic respiratory diseases Year: 2012 Clinical and histological impact of omalizumab in oral corticosteroid-dependent severe allergic asthma Source: International Congress 2019 – Novel findings from asthma clinical trials Year: 2019 Treatment and outcomes in patients with asthma and allergic rhinitis Source: Eur Respir J 2005; 26: Suppl. 49, 576s Year: 2005 Anti-IgE therapy with omalizumab decreases exacerbations in patients with poorly controlled moderate-to-severe allergic asthma Source: Eur Respir J 2003; 22: Suppl. 45, 203s Year: 2003 Patients’ perception of allergic asthma and their compliance to omalizumab in an Italian clinical setting Source: International Congress 2017 – Asthma management Year: 2017 The evaluations of allergic rhinitis symptoms in patients with asthma and allergic rhinitis with the addiing of montelukast in asthma treatment Source: Eur Respir J 2004; 24: Suppl. 48, 124s Year: 2004 Treatment of co-morbid allergic asthma and perennial allergic rhinitis with the anti-IgE agent omalizumab Source: Eur Respir J 2003; 22: Suppl. 45, 203s Year: 2003